Giant Papillary conjunctivitis (GPC) is a syndrome frequently arising as a result of contact lens use related complication. It is an inflammatory condition also found to inflict those having ocular prosthesis or those people with exposed stitches secondary to surgical procedure.
Foremost appearance of symptoms might surface months or even years subsequent to eye contact usage being started. Several variables could have an impact on the inception and how severe the symptoms present themselves.
Symptoms of GPC
The earliest GPC symptoms could be faint and generally appearing prior to the signs. Itchiness soon following eye contacts being removed, mucus strands accruement in the nasal canthus, hyperemia of the upper palpebral conjunctiva and slight eyesight blurriness due to coating on the lens subsequent to a couple of hours of contact lens use are commonly observed early indications of GPC. In several situations, patients fail in reporting these signs since they presume that these are usually experienced signs linked to contact lens use. Later on the symptoms like a sense of foreign object being lodged in the eyes, blurry vision, lens dislocation and huge levels of mucous-like emission makes contact lenses wear unbearable.
Pink eye treatment choices for GPC
Rigid, gas-permeable eye contacts seem to cause lesser acute GPC signs and symptoms and more time prior to GPC developing. Non-ionic as compared to ionic, low water content soft contact lens is helpful in lessening acute GPC symptoms.
Enzymatic pink eye treatment seems to reduce acuteness of the symptoms. An allergy link seems to don a part in the inception of severity of signs however does not seem to have an impact on the eventual capability of the person to use eye contacts.
The use of multiple pink eye treatment choices like switching to rigid lens or glyceryl methyl methacrylate from polymer ones or using a soft contact lens that is regularly replaced could bring about a success rate of above ninety percent. Among individuals who continue to experience a relapse of symptoms, the usage of topically applied mast cell stabilizers or a NSAID (non-steroidal anti inflammatory drug) as an adjuvant treatment provides additional chances of keeping such people on eye contacts.
For mild GPC, lens materials could be changed such as those with greater deposit-resistant or FDA group I or switching to single-use contact lens (every day or week-by-week) could help in bringing significant improvement. Bringing about improvement in lens sanitation and employing non-preservative disinfectant and lubricant types could additionally help in controlling GPC. Those people at elevated risk of developing GPC should ideally replace contact lens at one to two weekly time intervals could provide an improved approach in preventing GPC as compared to including enzymatic cleaning into eye care routine.
In case of moderate GPC, the usage of novel duo-acting medicines such as ketotifen, olopatadine which merge mast cell stabilizer effects alongside antihistamine taken two times per day for eight to twelve weeks would be an effectual substitute treatment choice.
For acute GPC cases, the usage of loteprednol, a soft-textured, safe steroidal choice that provides swift curative response merged with less occurrence of intraocular pressure rise would make it an apt therapy for acute GPC.
